https://www.selleckchem.com/pr....oducts/simnotrelvir.
In patients tapering HCQ, baseline prednisone use was independently associated with greater risk of poor outcomes. In the discontinuation cohort, risk of poor outcomes was greater for blacks and those diagnosed with SLE at age ≤25 years. Among those maintaining HCQ, baseline immunosuppressive use and First Nation ethnicity were associated with poor outcomes. We identified demographic and clinical factors associated with poor outcomes after HCQ taper/discontinuation. This information is critical in the current setting of potential s
Like
Comment
Share
